Recent Advances in Cancer Stem Cell-Targeted Immunotherapy

Cancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors...

Full description

Bibliographic Details
Main Authors: Narayanasamy Badrinath, So Young Yoo
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Cancers
Subjects:
Online Access:http://www.mdpi.com/2072-6694/11/3/310
id doaj-21e0dbbf74194191ae2295358e6eb115
record_format Article
spelling doaj-21e0dbbf74194191ae2295358e6eb1152020-11-25T01:23:59ZengMDPI AGCancers2072-66942019-03-0111331010.3390/cancers11030310cancers11030310Recent Advances in Cancer Stem Cell-Targeted ImmunotherapyNarayanasamy Badrinath0So Young Yoo1Biomedical Sciences, School of Medicine, Pusan National University, Yangsan 50612, KoreaResearch Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, KoreaCancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors, CSCs have to be targeted. Recent advances in immunotherapies have shown promising outcomes in curing cancer, which are also applicable to target CSCs. CSCs express immune markers and exhibit specific immune characteristics in various cancers, which can be used in immunotherapies to target CSCs in the tumor microenvironment. Recently, various strategies have been used to target CSCs. Adaptive T-cells, dendritic cell (DC)-based vaccines, oncolytic viruses, immune checkpoint inhibitors, and combination therapies are now being used to target CSCs. Here, we discuss the feasibility of these immunological approaches and the recent trends in immunotherapies to target CSCs.http://www.mdpi.com/2072-6694/11/3/310cancer stem cellsimmunotherapycombination therapy
collection DOAJ
language English
format Article
sources DOAJ
author Narayanasamy Badrinath
So Young Yoo
spellingShingle Narayanasamy Badrinath
So Young Yoo
Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
Cancers
cancer stem cells
immunotherapy
combination therapy
author_facet Narayanasamy Badrinath
So Young Yoo
author_sort Narayanasamy Badrinath
title Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
title_short Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
title_full Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
title_fullStr Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
title_full_unstemmed Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
title_sort recent advances in cancer stem cell-targeted immunotherapy
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-03-01
description Cancer stem cells (CSCs) are one of the reasons for the relapse of cancer cells and metastasis. They have drug resistance against most chemotherapeutic agents. CSCs are also responsible for tumor cell heterogeneity and cause minimal residual disease. In order to achieve complete regression of tumors, CSCs have to be targeted. Recent advances in immunotherapies have shown promising outcomes in curing cancer, which are also applicable to target CSCs. CSCs express immune markers and exhibit specific immune characteristics in various cancers, which can be used in immunotherapies to target CSCs in the tumor microenvironment. Recently, various strategies have been used to target CSCs. Adaptive T-cells, dendritic cell (DC)-based vaccines, oncolytic viruses, immune checkpoint inhibitors, and combination therapies are now being used to target CSCs. Here, we discuss the feasibility of these immunological approaches and the recent trends in immunotherapies to target CSCs.
topic cancer stem cells
immunotherapy
combination therapy
url http://www.mdpi.com/2072-6694/11/3/310
work_keys_str_mv AT narayanasamybadrinath recentadvancesincancerstemcelltargetedimmunotherapy
AT soyoungyoo recentadvancesincancerstemcelltargetedimmunotherapy
_version_ 1725119588298915840